TW200833372A - Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound - Google Patents

Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound

Info

Publication number
TW200833372A
TW200833372A TW96139674A TW96139674A TW200833372A TW 200833372 A TW200833372 A TW 200833372A TW 96139674 A TW96139674 A TW 96139674A TW 96139674 A TW96139674 A TW 96139674A TW 200833372 A TW200833372 A TW 200833372A
Authority
TW
Taiwan
Prior art keywords
release
active compound
meth
decreasing
influence
Prior art date
Application number
TW96139674A
Other languages
Chinese (zh)
Inventor
Hans-Ulrich Petereit
Brigitte Skalsky
Diego Gallardo
Manfred Assmus
Andreas Gryczke
Wolfgang Weisbrod
Felix Hofmann
Hans Baer
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of TW200833372A publication Critical patent/TW200833372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

The invention relates to the use of gastric juice-insoluble (meth)acrylate copolymers in oral delayed-release pharmaceutical forms as a matrix-forming agent for the active compound contained for decreasing the effect of the acceleration or slowing of the release of active compound as a result of the influence of ethanol under in-vitro conditions.
TW96139674A 2006-10-26 2007-10-23 Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound TW200833372A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE200610051020 DE102006051020A1 (en) 2006-10-26 2006-10-26 Use of enteric (meth)acrylate copolymers in controlled-release oral pharmaceutical dosage forms as drug matrix formers to reduce the effect of ethanol-induced release rate increase or decrease in vitro

Publications (1)

Publication Number Publication Date
TW200833372A true TW200833372A (en) 2008-08-16

Family

ID=38521102

Family Applications (1)

Application Number Title Priority Date Filing Date
TW96139674A TW200833372A (en) 2006-10-26 2007-10-23 Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound

Country Status (3)

Country Link
DE (1) DE102006051020A1 (en)
TW (1) TW200833372A (en)
WO (1) WO2008049657A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2923102C (en) 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
KR101528957B1 (en) 2008-09-24 2015-06-17 에보니크 룀 게엠베하 Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
CN104984343B (en) * 2008-09-24 2019-04-02 赢创罗姆有限公司 The pharmaceutical composition of the dependent controlled release of pH for the non-opium drug that ethanol tolerant influences
JP5453434B2 (en) 2008-09-24 2014-03-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング Non-opioid pH-dependent controlled release pharmaceutical composition resistant to the effects of ethanol
WO2010105672A1 (en) * 2009-03-18 2010-09-23 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
CN105287434A (en) * 2009-03-18 2016-02-03 赢创罗姆有限公司 Ethanol influence-resistant controlled-release medicine composition adopting coating containing neutral vinyl polymers and excipients
CN102365083A (en) * 2009-03-18 2012-02-29 赢创罗姆有限公司 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
JP5671609B2 (en) 2010-05-10 2015-02-18 ユーロ−セルティーク エス．エイ． Pharmaceutical composition comprising hydromorphone and naloxone
BR112012028656A2 (en) * 2010-05-10 2016-08-09 Euro Celtique Sa combination of active loaded granules with additional assets
WO2011141489A1 (en) * 2010-05-10 2011-11-17 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
HUE030548T2 (en) 2011-06-17 2017-05-29 Evonik Roehm Gmbh Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
CN103501767A (en) 2011-06-17 2014-01-08 赢创罗姆有限公司 Coating composition suitable for pharmaceutical or nutraceutical dosage forms
HUE033111T2 (en) 2011-06-17 2017-11-28 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
EP2976082A4 (en) 2013-03-15 2016-05-11 Inspirion Delivery Technologies Llc Abuse deterrent compositions and methods of use
KR102194174B1 (en) 2013-11-13 2020-12-23 유로-셀티큐 에스.에이. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2020182596A1 (en) 2019-03-11 2020-09-17 Evonik Operations Gmbh Dosage form comprising a polymeric matrix

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US20020106412A1 (en) * 2000-07-10 2002-08-08 Therics, Inc Method and materials for controlling migration of binder liquid in a powder
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE10058771A1 (en) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Coacervation process for the production of delayed-release drugs
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
FI1765303T4 (en) * 2004-07-01 2023-01-31 Oral tablet safeguarded against abuse
CN101132772B (en) * 2005-01-28 2012-05-09 欧洲凯尔特公司 Alcohol resistant dosage forms
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
SG169334A1 (en) * 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists

Also Published As

Publication number Publication date
DE102006051020A1 (en) 2008-04-30
WO2008049657A3 (en) 2008-10-30
WO2008049657A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
PL1906939T3 (en) Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values
WO2006084164A3 (en) Gastric retention and controlled release delivery system
EP2045251A4 (en) Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses
PL2457563T3 (en) Zero-order modified release solid dosage forms
EP2174667A4 (en) Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
ZA200904436B (en) Modified release ibuprofen solid oral dosage form
TR201902010T4 (en) Delivery device for oral administration of an agent.
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2011101866A3 (en) Gastric retention formulation containing baclofen
UA92641C2 (en) Pharmaceutical composition comprising amlodipine and losartan
CO6440564A2 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE
MY148496A (en) Dpp iv inhibitor formulations
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
WO2008022974A3 (en) Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
TW200806282A (en) Solid dosage formulations
BRPI0817275A2 (en) Pharmaceutical combination of aliskiren and valsartan
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
WO2008005353A3 (en) Immediate-release tablet formulations of a thrombin receptor antagonist
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
WO2006109344A3 (en) Composition to be used for the treatment of parodontal pathologies
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole
WO2008035229A3 (en) Compositions and methods for ph targeted drug delivery
WO2008070495A3 (en) Short term slow release drug delivery system